MD: Mr. Smith, your wife is seriously ill and now classified as Critical. She is now ventilated and that stage presents some challenges. We would like you to consider an experimental monoclonal antibody called Vyrologix.
Mr. Smith: What about the MAB.
MD: In early trials it has reduced patients in critical condition's mortality by 24%. The trials also demonstrated a 166% better likelihood of leaving the hospital alive than standard care. Also, patients treated tend to leave the hospital 6 days sooner than just the standard care your wife is getting now.
Mr. Smith: Wow! How safe is it?
MD: In close to 2,000 treatments there has never been a severe adverse event.
Mr. Smith: REALLY?????
MD: Yes!
Mr. Smith: Can you think of any reason not to try it?
MD: It's still experimental and not FDA approved, but she can get it thru eIND processing.
Mr. Smith: Hell yes! Let's do it!
If you're negative about the recent data PR'd yesterday what would you're answer be?
Mr. Smith: What about the MAB.
MD: In early trials it has reduced patients in critical condition's mortality by 24%. The trials also demonstrated a 166% better likelihood of leaving the hospital alive than standard care. Also, patients treated tend to leave the hospital 6 days sooner than just the standard care your wife is getting now.
Mr. Smith: Wow! How safe is it?
MD: In close to 2,000 treatments there has never been a severe adverse event.
Mr. Smith: REALLY?????
MD: Yes!
Mr. Smith: Can you think of any reason not to try it?
MD: It's still experimental and not FDA approved, but she can get it thru eIND processing.
Mr. Smith: Hell yes! Let's do it!
If you're negative about the recent data PR'd yesterday what would you're answer be?
6
